Last reviewed · How we verify

NCT03781258

Anti-thrombotic Monotherapy in HeartMate 3 Left Ventricular Assist System (LVAS)

Status unknown NA Last updated 4 August 2020
What this trial tests

NA trial testing Warfarin in Heart Failure in 20 participants. Status unknown.

Timeline
23 November 2018
Primary endpoint
31 December 2021
31 December 2021

Quick facts

Lead sponsorInstitute for Clinical and Experimental Medicine
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment20
Start date23 November 2018
Primary completion31 December 2021
Estimated completion31 December 2021
Sites1 location across Czechia

Drugs / interventions tested

Conditions studied

Sponsor

Institute for Clinical and Experimental Medicine

Who can join

18 and older, any sex, with Heart Failure or Cardiovascular Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this prospective controlled study is to obtain a multi-center safety and feasibility data on patients managed with anti-thrombotic monotherapy with HeartMate 3 LVAS.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Warfarin

Trials testing the same drug.

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

Other Institute for Clinical and Experimental Medicine trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03781258.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing